Osteoarthritis (OA) affects over 240 million adults worldwide. Placental‐derived tissues and fluids are known to contain anti‐inflammatory and immunomodulatory cytokines and growth factors. A study published in the Journal of Orthopaedic Research in December of 2019 evaluated the anti‐inflammatory effects of amniotic suspension allograft (ASA) in an in-vivo model of OA, evaluating pain, function, and cytokine levels following ASA treatment in a rat osteoarthritis pain model.
The researchers inducted OA disease among the subjects and seven days later, treated the subjects with 50 μl of amniotic suspension allograft, which showed a significant improvement in pain threshold levels at day 14 that was sustained until study completion (21 days) compared with controls. The results suggested improvements in pain threshold, as well as a decrease in weight bearing aversion and swelling.
Dr. Andre Terzic, director of the Center for Regenerative Medicine at Mayo Clinic states that “The future [of regenerative medicine] is remarkable. The word ‘cures’ will be increasingly real.”
Amniotic fluid specifically is utilized in Russell Health’s Stem Cell Recruitment Therapy™ to treat a number of physical ailments, including osteoarthritis. Patients have found great relief after a single dose of this potent and natural injection. Patient Duane D. is a 61 year old male farmer who had osteoarthritis and torn tissue in both of his shoulders. He could no longer work comfortably, lift his grandkids, or sleep through the night. He was told he needed to have surgery on both of his shoulders. After learning about Stem Cell Recruitment Therapy™ and some of the products being covered by Medicare, he received amniotic fluid injections in both of his shoulders.
“It’s been over a year now since my injections, and the recovery has been amazing. It has truly changed my life. I tell everyone who is in pain about Stem Cell Recruitment Therapy™.”